239 related articles for article (PubMed ID: 7509389)
1. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
Akiyama T; Otsuki M
Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin antagonistic activities of loxiglumide.
Wakatsuki K; Saito T; Saeki M; Ninomiya K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1997 Oct; 47(10):1130-3. PubMed ID: 9368707
[TBL] [Abstract][Full Text] [Related]
7. Selective activation by photodynamic action of cholecystokinin receptor in the freshly isolated rat pancreatic acini.
An YP; Xiao R; Cui H; Cui ZJ
Br J Pharmacol; 2003 Jun; 139(4):872-80. PubMed ID: 12813011
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats.
Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S
Pancreas; 1995 Apr; 10(3):295-300. PubMed ID: 7542771
[TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
[TBL] [Abstract][Full Text] [Related]
10. Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally.
Moriyoshi Y; Shiratori K; Iwabe C; Watanabe S; Takeuchi T
J Gastroenterol; 1996 Apr; 31(2):249-53. PubMed ID: 8680546
[TBL] [Abstract][Full Text] [Related]
11. Direct contractile effect of cholecystokinin octapeptide on caecal circular smooth muscle cells of guinea pig via both CCK-A and CCK-B/gastrin receptors.
Motomura Y; Chijiiwa Y; Iwakiri Y; Nawata H
Life Sci; 1997; 60(7):499-504. PubMed ID: 9042379
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats.
Tachibana I; Otsuki M
Dig Dis Sci; 1994 Jun; 39(6):1321-8. PubMed ID: 8200267
[TBL] [Abstract][Full Text] [Related]
14. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
Tachibana I; Kanagawa K; Yamamoto Y; Otsuki M
J Pharmacol Exp Ther; 1996 Dec; 279(3):1404-12. PubMed ID: 8968365
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
[TBL] [Abstract][Full Text] [Related]
17. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
20. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
